Triptolide reduces cystogenesis in a model of ADPKD

Stephanie J. Leuenroth, Natasha Bencivenga, Peter Igarashi, Stefan Somlo, Craig M. Crews

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Mutations in PKD1 result in autosomal dominant polycystic kidney disease, which is characterized by increased proliferation of tubule cells leading to cyst initiation and subsequent expansion. Given the cell proliferation associated with cyst growth, an attractive therapeutic strategy has been to target the hyperproliferative nature of the disease. We previously demonstrated that the small molecule triptolide induces cellular calcium release through a polycystin-2-dependent pathway, arrests Pkd1-/- cell growth, and reduces cystic burden in Pkd1-/- embryonic mice. To assess cyst progression in neonates, we used the kidney-specific Pkd1flox/-;Ksp- Cre mouse model of autosomal dominant polycystic kidney disease, in which the burden of cysts is negligible at birth but then progresses rapidly over days. The number, size, and proliferation rate of cysts were examined. Treatment with triptolide significantly improved renal function at postnatal day 8 by inhibition of the early phases of cyst growth. Because the proliferative index of kidney epithelium in neonates versus adults is significantly different, future studies will need to address whether triptolide delays or reduces cyst progression in the Pkd1 adult model.

Original languageEnglish (US)
Pages (from-to)1659-1662
Number of pages4
JournalJournal of the American Society of Nephrology
Volume19
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Autosomal Dominant Polycystic Kidney
Cysts
Kidney
Growth
Cell Proliferation
triptolide
Epithelium
Parturition
Calcium
Mutation

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Leuenroth, S. J., Bencivenga, N., Igarashi, P., Somlo, S., & Crews, C. M. (2008). Triptolide reduces cystogenesis in a model of ADPKD. Journal of the American Society of Nephrology, 19(9), 1659-1662. https://doi.org/10.1681/ASN.2008030259

Triptolide reduces cystogenesis in a model of ADPKD. / Leuenroth, Stephanie J.; Bencivenga, Natasha; Igarashi, Peter; Somlo, Stefan; Crews, Craig M.

In: Journal of the American Society of Nephrology, Vol. 19, No. 9, 09.2008, p. 1659-1662.

Research output: Contribution to journalArticle

Leuenroth, SJ, Bencivenga, N, Igarashi, P, Somlo, S & Crews, CM 2008, 'Triptolide reduces cystogenesis in a model of ADPKD', Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1659-1662. https://doi.org/10.1681/ASN.2008030259
Leuenroth, Stephanie J. ; Bencivenga, Natasha ; Igarashi, Peter ; Somlo, Stefan ; Crews, Craig M. / Triptolide reduces cystogenesis in a model of ADPKD. In: Journal of the American Society of Nephrology. 2008 ; Vol. 19, No. 9. pp. 1659-1662.
@article{4adc0dfc5d6940d59d3311748a3fdcd0,
title = "Triptolide reduces cystogenesis in a model of ADPKD",
abstract = "Mutations in PKD1 result in autosomal dominant polycystic kidney disease, which is characterized by increased proliferation of tubule cells leading to cyst initiation and subsequent expansion. Given the cell proliferation associated with cyst growth, an attractive therapeutic strategy has been to target the hyperproliferative nature of the disease. We previously demonstrated that the small molecule triptolide induces cellular calcium release through a polycystin-2-dependent pathway, arrests Pkd1-/- cell growth, and reduces cystic burden in Pkd1-/- embryonic mice. To assess cyst progression in neonates, we used the kidney-specific Pkd1flox/-;Ksp- Cre mouse model of autosomal dominant polycystic kidney disease, in which the burden of cysts is negligible at birth but then progresses rapidly over days. The number, size, and proliferation rate of cysts were examined. Treatment with triptolide significantly improved renal function at postnatal day 8 by inhibition of the early phases of cyst growth. Because the proliferative index of kidney epithelium in neonates versus adults is significantly different, future studies will need to address whether triptolide delays or reduces cyst progression in the Pkd1 adult model.",
author = "Leuenroth, {Stephanie J.} and Natasha Bencivenga and Peter Igarashi and Stefan Somlo and Crews, {Craig M.}",
year = "2008",
month = "9",
doi = "10.1681/ASN.2008030259",
language = "English (US)",
volume = "19",
pages = "1659--1662",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Triptolide reduces cystogenesis in a model of ADPKD

AU - Leuenroth, Stephanie J.

AU - Bencivenga, Natasha

AU - Igarashi, Peter

AU - Somlo, Stefan

AU - Crews, Craig M.

PY - 2008/9

Y1 - 2008/9

N2 - Mutations in PKD1 result in autosomal dominant polycystic kidney disease, which is characterized by increased proliferation of tubule cells leading to cyst initiation and subsequent expansion. Given the cell proliferation associated with cyst growth, an attractive therapeutic strategy has been to target the hyperproliferative nature of the disease. We previously demonstrated that the small molecule triptolide induces cellular calcium release through a polycystin-2-dependent pathway, arrests Pkd1-/- cell growth, and reduces cystic burden in Pkd1-/- embryonic mice. To assess cyst progression in neonates, we used the kidney-specific Pkd1flox/-;Ksp- Cre mouse model of autosomal dominant polycystic kidney disease, in which the burden of cysts is negligible at birth but then progresses rapidly over days. The number, size, and proliferation rate of cysts were examined. Treatment with triptolide significantly improved renal function at postnatal day 8 by inhibition of the early phases of cyst growth. Because the proliferative index of kidney epithelium in neonates versus adults is significantly different, future studies will need to address whether triptolide delays or reduces cyst progression in the Pkd1 adult model.

AB - Mutations in PKD1 result in autosomal dominant polycystic kidney disease, which is characterized by increased proliferation of tubule cells leading to cyst initiation and subsequent expansion. Given the cell proliferation associated with cyst growth, an attractive therapeutic strategy has been to target the hyperproliferative nature of the disease. We previously demonstrated that the small molecule triptolide induces cellular calcium release through a polycystin-2-dependent pathway, arrests Pkd1-/- cell growth, and reduces cystic burden in Pkd1-/- embryonic mice. To assess cyst progression in neonates, we used the kidney-specific Pkd1flox/-;Ksp- Cre mouse model of autosomal dominant polycystic kidney disease, in which the burden of cysts is negligible at birth but then progresses rapidly over days. The number, size, and proliferation rate of cysts were examined. Treatment with triptolide significantly improved renal function at postnatal day 8 by inhibition of the early phases of cyst growth. Because the proliferative index of kidney epithelium in neonates versus adults is significantly different, future studies will need to address whether triptolide delays or reduces cyst progression in the Pkd1 adult model.

UR - http://www.scopus.com/inward/record.url?scp=54749087598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749087598&partnerID=8YFLogxK

U2 - 10.1681/ASN.2008030259

DO - 10.1681/ASN.2008030259

M3 - Article

VL - 19

SP - 1659

EP - 1662

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 9

ER -